Analgesic effect of dezocine in radio frequency ablation for treatment of hepatic carcinoma

doi:10.3877/cma.j.issn.2095-5782.2018.02.004

Abstract

Abstract:

Objective:

To investigate the analgestic effect of dezocine in radio frequency ablation (RFA) for the treatment of hepatic carcinoma.

Methods:

Sixty patients with hepatic carcinoma were enrolled in this study. These patients were randomly divided into two groups: Group A (n=28) and Group B (n=30) . Before operation, the patients in Group A were IM given pethidine (75 mg) while the patients in Group B were treated with dezocine (0.1 mg/kg) . The visual analogue scale (VAS) and patients satisfaction scale were used to evaluate the comfort degree, and the incidence rates of adverse drug reactions were also recorded.

Results:

In the operation, the VAS score in Group B was lower than that of the Group A (3.3±1.7 vs. 5.9±1.4) and the difference was statistically significant (P<0.05) . After operation, the VAS score in Group B was lower than that of Group A (2.3±1.4 vs. 4.6±1.3) and the difference was statistically significant (P<0.05) . Satisfaction level (1:very good, 2:good, 3:general, 4:bad) in group B (8, 13, 7, 1) was better than that in group A (3, 10, 12, 5) and the difference was statistically significant (P<0.05) .

Conclusions:

The use of dezocine can ensure the completion of RFA operation for HCC, and the effect is better than that of pethidine.

Key words: Dezocine, Pethidine, Analgesia, Hepatic Carcinoma, Radio frequency albation

Yunliang Wang, Zhi Li, Lele Yan, Mingming Li, Jian Shen, Jianwei Zou. Analgesic effect of dezocine in radio frequency ablation for treatment of hepatic carcinoma[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2018, 06(02): 109-112.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2018.02.004

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2018/V06/I02/109

Figures/Tables 3

References 16

[1]	Zhu ZX, Huang JW, Liao MH, et al. Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection[J]. Jpn J Clin Oncol, 2016, 46(12):1075-1080.
[2]	李智，倪才方，李炜，等.基于电磁导航的影像引导系统在膈顶部肝癌消融中的应用[J].介入放射学杂志，2016，25(11):969-972.
[3]	Bian X, Zhou R, Yang Y, et al. Divergent effect of dezocine, morphine and sufentanil on intestinal motor function in rats[J]. Int J Med Sci, 2015, 12(11):848-852.
[4]	陈敏华.再论影像指导肝癌射频消融的规范化治疗[J].中华肿瘤杂志，2015，9:656-659.
[5]	佟小强，吕天石，宋莉，等. CT引导射频消融治疗肝癌[J].中华医学杂志，2015，95(27):2167-2169.
[6]	王黎洲，李兴，宋杰，等.不同麻醉方式在肝癌射频消融术中应用的探讨[J].介入放射学杂志，2015(9):781-784.
[7]	郑彬，佘守章.地佐辛在麻醉镇痛领域的应用进展[J].广东医学，2015，36(21):3266-3268.
[8]	Wang YX, Mao XF, Li TF, et al. Dezocine exhibits antihypersensitivity activities in neuropathy through spinal muopioid receptor activation and norepinephrine reuptake inhibition[J]. Sci Rep, 2017, 7:43137.
[9]	佘守章，许学兵.地佐辛——一个尚待进一步认识的独特镇痛药物[J].广东医学，2015，36(21):3261-3263.
[10]	夏凡，沈晓凤，张瑶，等.地佐辛复合丙泊酚用于人工流产手术的效果[J].临床麻醉学杂志，2016，32(5):500-501.
[11]	张佣来，沙蕊，刘晶宇，等.罗哌卡因浸润麻醉联合地佐辛静脉麻醉对食管癌根治术患者全麻恢复期应激反应的影响[J].临床麻醉学杂志，2016，2:139-143.
[12]	Xu BB, Zhao XL, Xu GP. Clinical study of anesthetization by dezocine combined with propofol for indolent colonoscopy[J]. World J Gastroenterol, 2016, 22(24):5609-5615.
[13]	Xu Y, Zhu Y, Wang S, et al. Dezocine attenuates fentanyl-induced cough in a dose-dependent manner-a randomized controlled trial[J]. Int J Clin Exp Med, 2015, 8(4):6091-6096.
[14]	Li NN, Huang YQ, Huang LE, et al. Dezocine antagonizes morphine analgesia upon simultaneous administration in rodent models of acute nociception[J]. Pain Physician, 2017, 20(3):E401-E409.
[15]	Li Z, Wu H, He R, et al. Oxycodone versus dezocine for postoperative analgesia in patients with cervical cancer treated with radical surgery[J]. J Cancer Res Ther, 2016, 12(Suppl):27-29.
[16]	Hiraoka A, Kumada T, Michitaka K, et al. Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation[J]. Mol Clin Oncol, 2017, 6(4):455-461.

组别	性别（男/女）	年龄（岁）	病灶数（枚）	病灶位置（深部/表浅，枚）
A组	23/7	64.3±8.1	42	20/22
B组	24/6	64.9±4.4	47	25/22
统计量	χ²=0.098	t=0.113	?	χ²=0.276
P值	0.754	0.916	?	0.600

组别	性别（男/女）	年龄（岁）	病灶数（枚）	病灶位置（深部/表浅，枚）
A组	23/7	64.3±8.1	42	20/22
B组	24/6	64.9±4.4	47	25/22
统计量	χ²=0.098	t=0.113	?	χ²=0.276
P值	0.754	0.916	?	0.600

组别	例数	VAS评分（分）		满意度评分				不良反应
组别	例数	术前	术后	1	2	3	4	不良反应
A组	30	5.9±1.4	4.6±1.3	3	10	12	5	5(16.7)
B组	30	3.3±1.7	2.3±1.4	8	13	7	1	2(6.7)
统计量	?	t=3.491	t=3.190	χ²=11.640				χ²=4.403
P值	?	0.025	0.036	0.009				0.044

组别	例数	VAS评分（分）		满意度评分				不良反应
组别	例数	术前	术后	1	2	3	4	不良反应
A组	30	5.9±1.4	4.6±1.3	3	10	12	5	5(16.7)
B组	30	3.3±1.7	2.3±1.4	8	13	7	1	2(6.7)
统计量	?	t=3.491	t=3.190	χ²=11.640				χ²=4.403
P值	?	0.025	0.036	0.009				0.044

Please choose a citation manager

Content to export